Today’s guest blog comes from Sunita Prasad, senior manager for Lilly’s MDR-TB Partnership in India.
Tuberculosis (TB) continues to pose a monumental global health challenge. The disease affected nine million people in 2013, and claimed 1.5 million lives. In India, 1,000 people die of TB daily, though the disease is fully curable.
Today's guest blog comes from Lilly's vice president of Global Health Programs, Evan Lee, M.D.
Having recently returned from the annual Union World Conference on Lung Health, I am struck by the signs of increased solidarity and urgency in the fight against tuberculosis (TB). As a physician, I can’t help but see parallels between the disease we are fighting and the promise of increased momentum in national and international efforts.
Most TB drugs currently approved for treatment are 50+ years old and are required to be taken over a 6-month period to be effective. Compliance with such a long treatment regimen is a challenge, limiting drugs’ effectiveness and contributing to the rise in MDR-TB. As part of its MDR-TB Partnership, Eli Lilly and Company formed innovative partnerships with the Infectious Disease Research Institute (IDRI) and the Bill and Melinda Gates Foundation to discover new and more effective TB drugs.
Today's guest blog comes from Lilly's Vice President of Global Health Programs, Evan Lee, M.D.
Americans have been paying close attention to Atlanta in the past several weeks, and not because the Braves have reignited playoff hopes. It’s because, as you’ve surely heard by now, two Americans who contracted Ebola in West Africa were flown to Emory Hospital in Atlanta for intensive care. People are worried about this deadly disease spreading in the U.S.
Today’s guest blog comes from He Zhijun, Lilly’s CSR Manager and Program Officer for the Lilly MDR-TB Partnership in China.
In late June, I organized our first media visit to the Heilongjiang Provincial Infectious Disease Hospital located in Harbin, the provincial capital of China’s Heilongjiang province. The hospital is one of six pilot centers from the Lilly-China Medical Association TB Society collaboration focused on enhancing clinical skills of tuberculosis (TB) physicians.
Today's guest blog comes from Lilly's Vice President of Global Health Programs and Access, Dr. Evan Lee.
In an encouraging move, the World Health Assembly has passed a formal, long-term resolution to stop TB. This means that all countries that participate in the World Health Organization have agreed to a concrete strategy – with clear targets – that could potentially rid the world of this dreadful disease.